The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Elkedonia will develop first-in-class Elk1 inhibitors for treatment-resistant depression, targeting neuroplasticity without psychedelic side effects.

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 ...

The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound ...

Most of the company’s new additions, if not already online, will be scheduled for commissioning, validation, or qualification ...

Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers ...

The company describes the compact system as ergonomically designed, providing precision dosing and production floor ...

Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving ...

How Techceuticals, PharmParts, and smart auction strategies are ushering in a new era of efficiency and innovation for CDMOs ...

ICH Q6B provides expectations and a clear framework for the structural characterization of biopharmaceutical products.